Chemomab Therapeutics Ltd. · NASDAQ:CMMB
Chemomab Therapeutics — Investor Presentation (October 2021)
26 slides from Chemomab Therapeutics's investor presentation, Oct 25, 2021
Slide 1: Pioneering Innovative Treatments for Fibrotic Diseases
Pioneering Innovative Treatments for Fibrotic DiseasesCorporate Overview | Non-Confidential | October 2021
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations
Slide 3: Investment Highlights
Discovery and development of innovative therapeutics for rare inflammatory and fibrotic diseases with high unmet need CM-101, a first-in-class CCL24 neutralizing monoclonal antibody targeting:Primary Sclerosing Cholangitis (PSC)Systemic Sclerosis (SSc)Liver fibrosis (MoA*) Conducting 2 Phase II clin
Slide 4: Experienced Management
Experienced Management ARNON AHARON, MDChief Medical Officer SIGAL FATTAL, CPAChief Financial Officer DALE PFOST, PhD Chief Executive Officer SHARON ELKOBI, MSc, MBAVP Business Development MICHAL SEGAL-SALTO, PhDVP Research and Development ADI MOR, PhDCo-founder & Chief Scientific Officer
Slide 5: Board of Directors and Scientific Advisory Board
Stephen Squinto, PhD Chairman of the Board Adi Mor, PhDCo-founder & Chief Scientific Officer Dale Pfost, PhD Chief Executive Officer Neil Cohen, MADirector Nissim Darvish, MD, PhDDirector Joel Maryles, CFA, MBADirector Alan Moses, MD Director Claude Nicaise, MDDirector Board of Directors Scientific
Slide 6: CM-101: Pipeline in a Product Addressing Fibrotic Diseases
Program Indication Target Discovery Preclinical Phase 1 Phase 2 Status CM-101 Primary Sclerosing Cholangitis CCL24 Enrolling PatientsTop Line Data 2H 2022 CM-101 Systemic Sclerosis CCL24 Initiation Expected In 1Q 2022 CM-101 Liver Fibrosis (MoA*) CCL24 Enrolling PatientsTop Line Data 1H 2022 Next-ge
Slide 7: CCL24 is a Novel Therapeutic Target for Fibrosis
CCL24 is a Novel Therapeutic Target for Fibrosis Critical Mediator Promoting Inflammation and Fibrosis CCL24 CCR3 CCL24-regulated cellsFibroblasts (liver, lung and skin), Immune and Epithelial cells Immune cell recruitment Fibroblast activation Tissue scarring, inflammatory-mediated damage, collagen
Slide 8: CM-101: A First-in-Class mAb Blocking CCL24
CCR3 Immune cell recruitment Fibroblast activation & proliferation CCL24 CM-101 Fibrosis Inflammation CM-101: A First-in-Class mAb Blocking CCL24 Dual Mechanism of Action Interfering with the Core Fibrotic Pathways CM-101 attenuates inflammation and fibrosis by inhibiting fibroblast activation and i
Slide 9: Strong Preclinical Evidence of CM-101 via CCL24 Inhibition
Strong Preclinical Evidence of CM-101 via CCL24 Inhibition Significant Attenuation of Fibrosis & Inflammation Across a Wide Range of Models Primary sclerosing cholangitisANIT induced cholestasis-chronic and acute (mice)Bile duct ligation (rat)MDR2 knock-out (mice)Systemic sclerosisBleomycin-induced
Slide 10: Phase Ia Results: Double-Blind Randomized Escalating Dose
Double-Blind, Randomized Escalating Dose (N=32) CM-101 0.75 mg/kg IV or placebo (n=8) CM-101 2.5 mg/kg IV or placebo (n=8) CM-101 5 mg/kg IV or placebo (n=8) CM-101 10 mg/kg IV or placebo (n=8) Double-Blind, Randomized Single Dose (N=8) CM-101 5 mg/kg SC or placebo (n=8) IV Phase I End of 42 days fo
Slide 11: Phase Ib: Safe and Well Tolerated in NAFLD Patients
Wk 15End of treatment Wk 18End of study Double-Blind, Randomized Escalating Dose (N=16) CM-101 2.5 mg/kg IV or placebo (n=8) CM-101 5 mg/kg SC or placebo (n=8) Phase Ib Day 0Randomization Study population: NAFLD patients with normal liver functionMultiple CM-101 administrations were safe and well to
Slide 12: Phase Ib: Confirms CM-101 Anti-Fibrotic Mechanism in Humans
Phase Ib: Confirms CM-101 Anti-Fibrotic Mechanism in Humans Demonstrated Biomarker Improvement with Dose-Dependent PK-Target Engagement ProC4-Procollagen 4TIMP1- metallopeptidase inhibitor 1EOT-End of Treatment PK-Target Engagement PK-PD 2.5mg/kg IV PK-PD 5mg/kg SC Liver Stiffness Relative change fr
Slide 13: CM-101 for the Treatment of Primary Sclerosing Cholangitis
CM-101 for the Treatment of Primary Sclerosing Cholangitis
Slide 14: Primary Sclerosing Cholangitis (PSC)
Source: Johns Hopkins Medicine Primary Sclerosing Cholangitis (PSC) PSC is a rare, chronic liver disease characterized by progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts leading to end-stage liver disease and cirrhosisDiagnosis is most
Slide 15: CCL24 Plays a Key Role in PSC
CCL24 serum level in PSC patients Healthy Liver Collaboration with RFH, UK PSC Liver CCL24 STAINING CCL24 expression is significantly and selectively elevated in PSC livers CCL24 level in healthy vs PSC patients' livers tissues CCL24 correlates with ELF in PSC patients with elevated ALP CCL24 Plays
Slide 16: CM-101 Reduces Liver Fibrosis by 82%
% Fibrosis (sirius red staining) 82% reduction Col1A1Col3A1TIMP1ACTA2TGF-β ALTASTALP Liver enzymes Pro-fibrotic genes CM-101 Reduces Liver Fibrosis by 82% Segal-Salto et al, JHEP reports 2020TAA- Thioacetamide Reduced Liver Collagen in TAA Liver Fibrosis Rat Model Using Therapeutic Design HEALTHY TA
Slide 17: CM-101 Ameliorates Liver Injury and Fibrosis in PSC
CM-101 Ameliorates Liver Injury and Fibrosis in PSC Cholestasis, Inflammation and Fibrosis are Reduced in the MDR2 Knockout Model in Mice Macrophages (IBA1) Mdr2 -/- + CM-101 Cholangiocytes (panck) Sirius Red Mdr2 -/- Mdr2 -/- Reduced Macrophage Number Mdr2 -/- + CM-101 Mdr2 -/- Mdr2 -/- + CM-101 CM
Slide 18: Phase II PSC Study Trial Design
IV Administrations of CM-101 vs. Placebo; Q3W Week 12Last Dose CM-101 (10mg/kg) Placebo Day 0Randomization n=30 n=30 n=15 Primary endpoints: Serum alkaline phosphatase Change from baseline to W15 ELF score Change from baseline to W15 Secondary endpoints: Fibrotic biomarkers and liver enzymes (e.g. A
Slide 19: CM-101 for the Treatment of Systemic Sclerosis
CM-101 for the Treatment of Systemic Sclerosis
Slide 20: Systemic Sclerosis (SSc)
Systemic Sclerosis (SSc) Rare autoimmune rheumatic disease characterized by inflammation and fibrosis of the internal organs as well as vasculopathyAge of diagnosis 30-50 years, Predominantly affects women (3:1 female:male ratio)There is no approved disease modifying drug; Treatments focus on managi
Slide 21: CCL24: A Critical Node Potentiating Systemic Sclerosis
CCL24: A Critical Node Potentiating Systemic Sclerosis (SSc) Clinical Relevance of CCL24 in SSc Pathophysiology is Supported by Patient Samples dSSc – diffuse systemic sclerosisMor A et al., Annals of Rheumatic Diseases, 2019***p ≤0.001 CCL24 overexpressed in skin and serum samples of dSSc Patients
Slide 22: CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis
CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis Knocking Out the CCL24 Gene Attenuates Inflammation and Fibrosis in SSc Bleomycin Experimental Model Mor A et al., Annals of Rheumatic Diseases, 2019BLM – Bleomycin; WT - Wild type; KO – Knockout, BAL- Bronchoalveolar lavage, PBS- Phospha
Slide 23: CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc Models
CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc Experimental Models Relevant to Systemic Sclerosis Using Prevention and Therapeutic Designs Mor et al, Annals of Rheumatoid Diseases, 2019**p ≤0.01; *p ≤0.05. BLM - bleomycin; IT - Intratracheal; SC – SubcutaneousIgG - Immunoglobulin G Attenuat
Slide 24: CM-101 Clinical Development Plan and Key Catalysts
CM-101 Clinical Development Plan and Key Catalysts SC – Subcutaneous, MoA- Mechanism of Action *NCT04595825 Will be Advancing in Parallel Three Phase II Clinical Programs Status 2021 2022 2023 Primary Sclerosing Cholangitis EnrollingTop line data expected in 2H2022 Systemic Sclerosis Initiation expe
Slide 25: Investment Summary
Investment Summary Pioneering Innovative Treatment for Fibrosis-Related Diseases with High Unmet Need IV – Intravenous; SC – SubcutaneousMoA – Mechanism of Action Chemomab Clinical stage company advancing PhII trials in multiple fibrotic indications with high unmet need Substantial near term value i
Slide 26: Thank You
Presentation name Thank You
Chemomab Therapeutics — Investor Presentation (October 2021) on 6ix